Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Amphastar Pharmaceuticals (AMPH) EBITDA (2016 - 2025)

Historic EBITDA for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to $25.3 million.

  • Amphastar Pharmaceuticals' EBITDA fell 5561.63% to $25.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $149.9 million, marking a year-over-year decrease of 3001.75%. This contributed to the annual value of $205.4 million for FY2024, which is 428.05% up from last year.
  • Per Amphastar Pharmaceuticals' latest filing, its EBITDA stood at $25.3 million for Q3 2025, which was down 5561.63% from $42.2 million recorded in Q2 2025.
  • In the past 5 years, Amphastar Pharmaceuticals' EBITDA registered a high of $72.7 million during Q3 2023, and its lowest value of $10.3 million during Q1 2021.
  • Its 5-year average for EBITDA is $36.0 million, with a median of $36.9 million in 2023.
  • In the last 5 years, Amphastar Pharmaceuticals' EBITDA skyrocketed by 74237.58% in 2021 and then crashed by 5561.63% in 2025.
  • Quarter analysis of 5 years shows Amphastar Pharmaceuticals' EBITDA stood at $24.3 million in 2021, then soared by 56.0% to $37.8 million in 2022, then skyrocketed by 42.68% to $54.0 million in 2023, then fell by 16.37% to $45.1 million in 2024, then tumbled by 43.91% to $25.3 million in 2025.
  • Its EBITDA was $25.3 million in Q3 2025, compared to $42.2 million in Q2 2025 and $37.3 million in Q1 2025.